Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 2005

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

Clinical performance and menstrual bleeding patterns with three dosage

combinations of a Nestorone progestogen/ethinyl estradiol contraceptive

vaginal ring used on a bleeding-signaled regimen.

AUTHORS

Weisberg E; Brache V; Alvarez F; Massai R; Mishell DR Jr

SOURCE

Contraception. 2005;72:46-52.

ABSTRACT

Objective: We examined the clinical performance of contraceptive vaginal rings (rings) delivering Nestorone (NES)

progestin and ethinyl estradiol (EE). Ring removal times were signaled by menstrual events. Bleeding patterns,

adverse events, patterns of use and continuation rates were the principal parameters evaluated. Methods: In a two-

stage 6-month trial, subjects were randomized to use rings releasing 50 µg/day of NES and either 10 (50/10) or 20

(50/20) µg/day of EE. Subjects were to keep rings continuously in situ until menstrual bleeding or prolonged spotting-

signaled removal. Reinsertion was to occur 96 h later. After the randomized stage, an open-label 6-month trial of

rings releasing 150 µg/day of NES and 15 µg/day of EE (150/15) began with the same menstrually signaled regimen.

Results: Two-hundred forty-six subjects participated in the trial. Six-month pregnancy rates ranged by ring dose from

1.3 to 3.9 per 100. For each ring dose combination, 6-month continuation rates were above 80 per 100. Bleeding and

spotting (B+S) days in women with the 50 µg/day NES rings were similar in number to those experienced by cycling

women not using contraception. Nevertheless, in the initial 90 days, fewer B+S days were reported by subjects with

the 50/20 ring than by subjects with the 50/10 ring (p<.05). Throughout the trial, subjects using the 150/15 ring

reported significantly fewer B+S episodes than did subjects with either 50 µg/day NES ring. Conclusion: Combined

contraceptive rings used with a bleeding-signaled regimen led to few terminations attributed to bleeding problems

and to acceptable continuation rates. The 150/15 ring appeared to induce fewer bleeding problems than did the

lower-dose NES combination rings, but no important difference in 6-month continuation rates among the three doses

was noted. (PubHealth.info Document ID: CONT1T 80-06)

PubHealth.info NOTE: The author(s) of this article titled, "Clinical performance and menstrual bleeding patterns with

three dosage combinations of a Nestorone progestogen/ethinyl estradiol contraceptive vaginal ring used on a

bleeding-signaled regimen.", is(are) Weisberg E; Brache V; Alvarez F; Massai R; Mishell DR Jr. The source of

this article is "Contraception. 2005;72:46-52.". This article was published in 2005 in English language(s).

(PubHealth.info® Document ID: CONT1T 80-06. All rights reserved with PubHealth.info) PIN: 80

This article is peer-reviewed.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.